FOXP3 and neoplasm: CTLA4 is constitutively expressed in Foxp3+ Tregs and CTLA-4-specific antagonistic antibodies not only augment effector T-cell activation but also induce ADCC-mediated depletion of tumor-infiltrating Tregs (49–51).